WINTON GROUP Ltd Increases Position in STAAR Surgical Company $STAA

WINTON GROUP Ltd grew its holdings in STAAR Surgical Company (NASDAQ:STAA) by 14.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 147,822 shares of the medical instruments supplier’s stock after buying an additional 18,716 shares during the period. WINTON GROUP Ltd owned 0.30% of STAAR Surgical worth $3,413,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in STAA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of STAAR Surgical by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,390 shares of the medical instruments supplier’s stock valued at $518,000 after buying an additional 1,267 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of STAAR Surgical by 33.4% in the first quarter. Goldman Sachs Group Inc. now owns 544,843 shares of the medical instruments supplier’s stock valued at $9,606,000 after buying an additional 136,390 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of STAAR Surgical by 11.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 123,347 shares of the medical instruments supplier’s stock valued at $2,175,000 after buying an additional 12,841 shares during the last quarter. Creative Planning raised its holdings in shares of STAAR Surgical by 19.9% in the second quarter. Creative Planning now owns 15,695 shares of the medical instruments supplier’s stock valued at $263,000 after buying an additional 2,606 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in STAAR Surgical by 183.2% during the second quarter. JPMorgan Chase & Co. now owns 153,371 shares of the medical instruments supplier’s stock worth $2,574,000 after purchasing an additional 99,218 shares in the last quarter. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Stock Performance

NASDAQ STAA opened at $29.99 on Monday. The stock has a market capitalization of $1.49 billion, a P/E ratio of -69.74 and a beta of 1.23. STAAR Surgical Company has a 52-week low of $15.59 and a 52-week high of $35.87. The firm has a 50-day moving average price of $26.58 and a 200 day moving average price of $23.11. The company has a quick ratio of 4.31, a current ratio of 5.12 and a debt-to-equity ratio of 0.09.

STAAR Surgical (NASDAQ:STAA) last posted its quarterly earnings results on Wednesday, May 13th. The medical instruments supplier reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.05. STAAR Surgical had a negative net margin of 7.24% and a positive return on equity of 3.31%. The firm had revenue of $93.52 million during the quarter, compared to analysts’ expectations of $78.72 million. During the same period in the prior year, the company posted ($1.10) earnings per share. The firm’s revenue for the quarter was up 119.6% on a year-over-year basis. Equities research analysts expect that STAAR Surgical Company will post 0.13 EPS for the current year.

Insiders Place Their Bets

In related news, Director Broadwood Partners, L.P. bought 316,017 shares of the stock in a transaction on Friday, March 13th. The shares were bought at an average cost of $18.61 per share, for a total transaction of $5,881,076.37. Following the completion of the transaction, the director owned 16,123,842 shares of the company’s stock, valued at $300,064,699.62. This represents a 2.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have bought 670,213 shares of company stock worth $12,266,249 in the last quarter. Corporate insiders own 39.90% of the company’s stock.

Wall Street Analysts Forecast Growth

STAA has been the subject of several analyst reports. Mizuho increased their price target on shares of STAAR Surgical from $22.00 to $27.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Piper Sandler increased their price target on shares of STAAR Surgical from $16.00 to $33.00 and gave the stock a “neutral” rating in a report on Thursday, May 14th. Weiss Ratings cut shares of STAAR Surgical from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 22nd. Stifel Nicolaus increased their price target on shares of STAAR Surgical from $18.00 to $31.00 and gave the stock a “hold” rating in a report on Thursday, May 14th. Finally, Wells Fargo & Company increased their price target on shares of STAAR Surgical from $16.00 to $25.00 and gave the stock an “equal weight” rating in a report on Friday, May 15th. Three equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $27.81.

STAAR Surgical Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists.